About the ARMANI Trial

Table of Contents

Major Presentations and Milestones

ARMANI Trial design, results, and conclusions

ARMANI Sentiments and Criticisms

ARMANI Temporal Sentiment Arc

Professional Resources : Interactive Tweet History, Influence Diagram, Sentiment Table, AI Chatbot

ARMANI Trial: Major Presentations and Milestones

Primary speakers driving the story

Filippo Pietrantonio, MD (Istituto Nazionale dei Tumori, Milan) presented the phase 3 ARMANI trial at ASCO 2024, evaluating switch maintenance with paclitaxel plus ramucirumab versus oxaliplatin-based chemotherapy continuation in advanced HER2‑negative gastric or gastroesophageal junction (GEJ) cancer after 3 months of induction FOLFOX/CAPOX. Discussant Nataliya Uboha, MD, PhD (UW Carbone) contextualized the findings alongside EA2174 and RENAISSANCE, focusing on applicability in today’s biomarker‑driven first‑line landscape. Clinician coverage emphasized significant PFS and OS gains with ARMANI’s strategy, balanced by higher grade ≥3 toxicity.

Arndt Vogel, MD (ASCO24): Key headline efficacy and safety metrics and a pragmatic take that switch maintenance is “a valid option” after induction FOLFOX.

Cathy Eng, MD (ASCO24): Fulfillment of the PFS primary endpoint with HR 0.64 and explicit toxicity caveat.

Sharlene Gill, MD, MPH, MBA (ASCO24): Baseline context and the key question of positioning vis‑à‑vis first‑line immunotherapy and emerging strategies.

ARMANI Trial Design, Results, and Conclusions

Trial Design:

Phase 3, HER2‑negative advanced gastric/GEJ adenocarcinoma. After 3 months of induction FOLFOX or CAPOX, patients with CR/PR/SD were randomized 1:1 to switch maintenance with paclitaxel plus ramucirumab versus continuation of FOLFOX/CAPOX (followed by fluoropyrimidine maintenance per schema). Reported stratification factors included prior gastrectomy (Y/N), peritoneal disease (Y/N), and primary site (gastric vs GEJ). Randomized population ~280 (Arm A n~144, Arm B n~136 per KM at‑risk tables).

Primary Results:

PFS (primary endpoint) improved with switch maintenance: median 6.6 vs 3.5 months, HR 0.64 (95% CI 0.49–0.81), p<0.001. OS improved: median 12.6 vs 10.4 months, HR 0.75 (95% CI 0.58–0.97), p=0.028. Multiple on‑session summaries also reported ORR 19% vs 15.7% and a 24‑month restricted mean PFS increase of ~2.4 months in the experimental arm.

Safety:

Grade ≥3 treatment‑related adverse events were higher with paclitaxel+ramucirumab: 40.4% vs 20.7%. Notable events included neutropenia (grade ≥3 ~26% vs ~10%), hypertension (grade ≥3 ~6% vs ~0%), and peripheral neuropathy (any‑grade ~62% vs ~45%), consistent with known taxane/anti‑VEGFR profiles.

Key Conclusions:

Switch maintenance with paclitaxel plus ramucirumab after induction FOLFOX/CAPOX significantly prolongs PFS and OS versus continuing oxaliplatin‑based chemotherapy, at the cost of higher grade ≥3 toxicity. Presenters and discussants noted that ARMANI is most relevant for patients not receiving upfront PD‑1–based regimens or those ineligible for immunotherapy; positioning in current biomarker‑driven first‑line pathways remains an area for clinical judgment and further study.

ARMANI Sentiments and Criticisms

Positive Reception:

Massimo Di Maio: "Brilliant presentation of the Italian ARMANI trial by @FilippoPietran4 at #ASCO24. Bravo Filippo, as usual, and bravo to all investigators" https://x.com/MassimoDiMaio75/status/1798014085340270899

Noelle LoConte, MD: "ARMANI study supports chemo switch to pacli/ram after three months of FOLFOX for gastric ca with survival advantage" https://x.com/loconte/status/1798012783415767104

VJ Oncology summarized biomarker niche: "ARMMANI study on HER2-negative gastric/GEJ cancer with low/absent PD-L1. Paclitaxel + ramucirumab improved PFS … and OS …" https://x.com/VJOncology/status/1807051645471097127

Balancing Efficacy and Toxicity; Fit in IO Era:

Sharlene Gill, MD, MPH, MBA: "…impr PFS (+3.2m, HR0.62), and OS 12.6v10.4m, HR0.75 … increased toxicity! 🤔Where does this fit with 1L IO and emerging…" https://x.com/GillSharlene/status/1798018510792052889

Cathy Eng, MD: "Fulfilled the primary endpoint: PFS = 6.6M vs. 3.5M (HR = 0.64) but noted⬆️ toxicities (40.4 vs.…)" https://x.com/CathyEngMD/status/1798015028735447098

Emil Lou, MD, PhD: "ARMANI is an interesting therapeutic strategy … If toxicities can be reduced, it’s an approach to investigate in additional settings." https://x.com/cancerassassin1/status/1798014766495277299

ARMANI Temporal Sentiment Arc

Pre‑ASCO24 (Tease and anticipation)

• https://x.com/marklewismd/status/1783267445798830086
• Tone: Lighthearted anticipation as ARMANI became a talking point ahead of ASCO.
• Shift: Set the stage for first public presentation of mature efficacy data.

ASCO24 (Initial efficacy and safety readout)

Primary/KOL tweets:

• https://x.com/jgong15/status/1798013045568069737
• https://x.com/OsamaMosalemMD/status/1798017040910786744
• https://x.com/CathyEngMD/status/1798016450013339818
• Tone: Clear recognition of clinically meaningful PFS/OS gains with switch maintenance; immediate emphasis on toxicity and real‑world positioning relative to IO‑based first‑line therapy.
• Shift: From headline efficacy to operational fit—who benefits most, when to deploy, and toxicity mitigation.

Mid‑2024 (Post‑ASCO reflections and interviews)

Primary/KOL tweets:

• https://x.com/GillSharlene/status/1798018510792052889
• https://x.com/MassimoDiMaio75/status/1798014085340270899
• Tone: Continued positive interpretation of efficacy; growing focus on identifying the right biomarker contexts (e.g., low/absent PD‑L1, no upfront IO) and acknowledging toxicity trade‑offs.
• Shift: From trial results to practice implementation in selected patient subsets not receiving IO in first line.

Overall arc: Enthusiasm for a pragmatic, non‑IO maintenance strategy with OS benefit, tempered by higher toxicity and the need to define optimal use in an IO‑first era. Subsequent discussions stressed patient selection and toxicity management to translate ARMANI into practice.

ARMANI Professional Resources